Skip to content
OpenCapital
Get started

Ultragenyx Pharmaceutical RARE EV / sales

EV / sales at other companies

Eli Lilly logo
Eli LillyLLY
11.9×-4.0×
Amgen logo
AmgenAMGN
6.6×+0.1×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
12.2×+5.7×
Arrowhead Research logo
Arrowhead ResearchARWR
14×+10.9×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
1,201.6×+1,125×
Moderna logo
ModernaMRNA
8.8×+5.6×

Other financials

Income statement

See full
Revenue$136.0M-2.2%
Operating income-$169.0M-18.2%
Net income-$185.0M-22.5%
EPS (diluted)-$1.84-17.2%

Balance sheet

See full
Cash & equivalents$175.0M+37.8%
Total debt$36.0M-10.8%
Total equity-$236.0M-264%
Total assets$1.3B-1.2%

Cash flow

See full
Operating cash flow-$197.0M-18.7%
CapEx$1.0M0.0%
Free cash flow-$198.0M-18.6%

Valuation

See full
Market cap$2.83B-39.4%
P/S4.2×-3.7×

Profitability

See full
Gross margin97.2%—
Operating margin-83.8%-3.0pp
Net margin-90.9%-2.1pp
FCF margin-75.1%+10.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×—
Current ratio2×-0.4×

Where this comes from

Calculated from Ultragenyx Pharmaceutical’s reported figures.

enterprise value/total revenue=2.7×

Based on the most recent quarter.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's EV / sales?
Ultragenyx Pharmaceutical (RARE) reported EV / sales of 2.7× in Q4 2025.
How has Ultragenyx Pharmaceutical's EV / sales changed year-over-year?
Ultragenyx Pharmaceutical's EV / sales decreased by 59.3% year-over-year, from 6.7× to 2.7×.
What is the long-term trend for Ultragenyx Pharmaceutical's EV / sales?
Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's EV / sales has grown at a -39.0% compound annual growth rate (CAGR), from 32.4× to 2.7×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.